Eris Lifesciences Limited Total Liabilities
Eris Lifesciences Limited total liabilities. Based on the latest financial reports, Eris Lifesciences Limited (ERIS) has total liabilities worth Rs34.70 Billion INR (≈ $375.25 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Eris Lifesciences Limited to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Eris Lifesciences Limited (2012–2026)
Total liabilities of Eris Lifesciences Limited from 2012 to 2026. This chart illustrates how Eris Lifesciences Limited's total liabilities have evolved over time, based on quarterly financial data. Explore ERIS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Eris Lifesciences Limited Competitors by Total Liabilities
The table below lists competitors of Eris Lifesciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.07 Billion |
|
Nanjing Sunlord Electronics Corporation LTD
SHE:300975
|
China | CN¥7.37 Billion |
|
Syngene International Limited
NSE:SYNGENE
|
India | Rs18.07 Billion |
|
Hyundai Doosan Infracore Co Ltd
KO:042670
|
Korea | ₩2.53 Trillion |
|
SK Bioscience Co Ltd
KO:302440
|
Korea | ₩847.96 Billion |
|
A10 Network
NYSE:ATEN
|
USA | $439.71 Million |
|
Genesis Energy LP
NYSE:GEL
|
USA | $4.30 Billion |
|
Charter Hall Long Wale REIT
AU:CLW
|
Australia | AU$2.01 Billion |
Liability Composition Analysis (2012–2026)
This chart breaks down Eris Lifesciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ERIS total asset value.
Liquidity & Leverage Metrics
Eris Lifesciences Limited Total Liabilities Ratios Explained
Eris Lifesciences Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eris Lifesciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eris Lifesciences Limited (2012–2026)
The table below shows the annual total liabilities of Eris Lifesciences Limited from 2012 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs34.70 Billion ≈ $375.25 Million |
-7.75% |
| 2025-03-31 | Rs37.61 Billion ≈ $406.78 Million |
-1.71% |
| 2024-03-31 | Rs38.27 Billion ≈ $413.85 Million |
+164.53% |
| 2023-03-31 | Rs14.47 Billion ≈ $156.45 Million |
+297.50% |
| 2022-03-31 | Rs3.64 Billion ≈ $39.36 Million |
+40.87% |
| 2021-03-31 | Rs2.58 Billion ≈ $27.94 Million |
+0.93% |
| 2020-03-31 | Rs2.56 Billion ≈ $27.68 Million |
-33.49% |
| 2019-03-31 | Rs3.85 Billion ≈ $41.62 Million |
-32.97% |
| 2018-03-31 | Rs5.74 Billion ≈ $62.09 Million |
+468.02% |
| 2017-03-31 | Rs1.01 Billion ≈ $10.93 Million |
+6.92% |
| 2016-03-31 | Rs945.34 Million ≈ $10.22 Million |
+7.80% |
| 2015-03-31 | Rs876.95 Million ≈ $9.48 Million |
-2.28% |
| 2014-03-31 | Rs897.40 Million ≈ $9.71 Million |
+47.18% |
| 2013-03-31 | Rs609.72 Million ≈ $6.59 Million |
+24.04% |
| 2012-03-31 | Rs491.55 Million ≈ $5.32 Million |
-- |
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more